Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02924272 · ClinicalTrials.gov registry record · Phase 2
Ixazomib Rollover Study
A Phase 2 study of Multiple Myeloma and Lymphoma, sponsored by Takeda.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 20
- Study locations
NCT02924272 is a Phase 2 study of Multiple Myeloma and Lymphoma that has completed, run by Takeda. The registered enrollment target is 32 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT02924272, a Phase 2 study of Multiple Myeloma and Lymphoma, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to provide continued access to ixazomib and/or other study drugs from an ixazomib parent study.
Conditions Studied
Interventions
- DRUG Ixazomib
Study Locations (20)
Other
- UZ Leuven - Leuven
- 1st Affiliated Hospital of Zhejiang University - Hangzhou
- Shanghai Chang Zheng Hospital - Shanghai
- University of Athens Medical School - Regional General Hospital Alexandra - Athens
- Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi - Lodz
- Centrum Onkologii Ziemi Lubelskiej - Lublin
- MTZ Clinical Research Sp z o o - Warsaw
- National University Hospital - Singapore
Ontario
- Princess Margaret Cancer Centre - Toronto
- University Health Network - Toronto
Beijing Municipality
- Peking University Third Hospital - Beijing
- Peking Union Medical College Hospital - Beijing
Tokyo
- Tokyo Metropolitan Komagome Hospital - Bunkyo-Ku
- Japanese Red Cross Medical Center - Shibuya-Ku
Georgia
- Emory University - Atlanta
Kentucky
- Appalachian Regional Healthcare - Hazard
Massachusetts
- Dana Farber Cancer Institute - Boston
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2016-12-16 |
| Est. Completion | 2024-07-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02924272
The ClinicalTrials.gov registry entry for NCT02924272 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (94% lower). The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Ixazomib is the first listed.
NCT02924272 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, Ontario, Beijing Municipality.
Frequently Asked Questions
What is clinical trial NCT02924272 about?
NCT02924272 is a clinical study titled "Ixazomib Rollover Study". The purpose of this study is to provide continued access to ixazomib and/or other study drugs from an ixazomib parent study.
What is the current status of trial NCT02924272?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2016-12-16. Estimated completion is 2024-07-03.
What conditions does trial NCT02924272 study?
This clinical trial studies the following conditions: Multiple Myeloma, Lymphoma, Amyloidosis.
What interventions are being tested in trial NCT02924272?
The interventions under investigation include: Ixazomib (DRUG).
Who is sponsoring clinical trial NCT02924272?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02924272 being conducted?
This trial has 20 study locations across Georgia, Kentucky, Massachusetts, Missouri, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.